Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label continuation of lurasidone after prior lurasidone studies
2011-000682-12Phase 3Completed
- Sponsor
- Sunovion
- Start
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lurasidone in schizophrenia and bipolar disorder (BD), sponsored by Sunovion. Primary endpoints: Long-term safety of lurasidone, Long-term tolerability of lurasidone and 1 more. Started Jul 2011; status: completed.
02
Drugs
lurasidone
03
Conditions
schizophreniabipolar disorder (BD)
Beyond the preview
Go deeper on 2011-000682-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000682-12.